Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLIO-XS15: Multi Peptide Vaccination with XS15 in Glioblastoma
NCT04842513Phase 1Completed
- Sponsor
- University Hospital Tübingen
- Start
- May 2021
- Primary completion
- Jul 2024
- Countries
- 1
01
Overview
Phase 1, open-label trial of XS15 in glioblastoma multiforme (GBM), sponsored by University Hospital Tübingen. Primary endpoint: Adverse Events. Started May 2021; status: completed.
02
Drugs
XS15
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT04842513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04842513.